During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
The company said it will use the funding to accelerate the launch of its core isotachophoresis platform for nucleic acid sample preparation.
The firms will collaborate to develop Synlogics pipeline of synthetic medicines using Ginkgo's microbial programming and optimization platform.
Consenting participants will have their deidentified sequence data used for research and will also have the chance to learn if they have clinically actionable results.
The companies signed an agreement earlier this year to jointly develop microbiome research services for international markets including a shotgun metagenomic sequencing-based service.
The partners are both "investing heavily" in the study and will have access to the data and to new technologies and interventions.
The testing programs are financially supported by the drugmakers, and will allow Invitae to provide free testing and genetic counseling for rare inherited retinal disease and primary immunodeficiencies.
In a pilot study, EMD Serono will have the genomes of lung cancer patients sequenced for research but participants will also gain access to their genomic data.
The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.
The Swedish company is developing sequencing- and PCR-based tests and services that quantify aberrations in DNA, RNA, and circulating tumor DNA.
With $46 million in total raised since its founding in 2016, the company hopes to scale its telegenetics services to meet national demand.
The company's clinical services revenues were down 34 percent year over year while product revenues ticked up 7 percent.
Oncore and its partners will commercialize GeneNews' ColonSentry test in all countries outside the US and Canada under the five-year exclusive agreement
The companies will work with collaborators at Stockholm University to integrate their respective technologies for in situ sequencing and tissue processing.
The firm will use the funding for working capital for the Cyto-Mine single-cell analysis platform, UK facility expansion, and a new US sales office and demo lab.
The company expects to offer 6.7 million common shares at a maximum offering price of $16 per share.
Bratislava-based HighChem offers software that is used by pharmaceutical and metabolomics laboratories for analyzing complex data and identifying small molecules.
The company sold 2.2 million shares at an average price of $22.73 per share under a $50 million at-the-market equity facility it filed in March 2019.
Biotage will provide systems and consumables from its analytical chemistry portfolio to be sold by Yingsheng under its own brand.
Cytobank provides a cloud- and machine learning-based software platform for multi-parametric single-cell data analysis, sharing, and archiving.
New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.
A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.
Broad Institute researchers describe an approach they've dubbed "DNA microscopy."
In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.